BresMed at Virtual ISPOR Europe 2021
This year’s theme for ISPOR is “Emerging Frontiers and Opportunities: Special Populations and Technologies.” While the conference is taking place virtually this year, we’re happy to still be contributing a range of workshops, panels and posters.
ISPOR normally provides us with the chance to catch up with the people we work with throughout the year, and though this year looks different we’re also still available to chat. You can contact us if you’d like to arrange a meeting or if you are attending the virtual event you can chat with us during the event by visiting our company page.
|Date & time||Code||Title||Discussion leaders|
|Wednesday 1 December 12:30 – 13:30||206WK||The Potential of R Shiny User Interfaces to Support Health Economic Decision Making||Paul Schneider, Gianluca Baio, Rose Hart, Robert Smith.|
|Thursday 2 December
11:00 – 12:00
|304WK||Open Source Health Economics and Outcomes Research: Why and How to Do It? How to Connect with Users?||Xavier Pouwels, Rose Hart, Stephanie Harvard, Howard Thom.|
|Friday 3 December
11:00 – 12:00
|403WK||SEE the Future: How Important Will Structured Expert Elicitation Become for HTA in the Next 5 Years?||James Horscroft, Laura Bojke, Jeremy Edward Oakley.|
|Date & time||Code||Title||Moderator||Panelists|
|Wednesday 1 December
16:00 – 17:00
|214IP||Is Regulatory Acceptance of Surrogate Endpoints for CAR-Ts a Sufficient Basis for Acceptance By HTA Bodies?||Daniel Gladwell||Oriana Ciani, Stephen Palmer, Adam Parnaby.|
|Clinical Outcomes: Oncology||POSA25||An Incremental Effectiveness Analysis of Avelumab in Combination With Axitinib for the Treatment of First-Line Advanced Renal Cell Carcinoma in Portugal||Silva Miguel L, Pinheiro B, Lopes R, Borges M, Kearney M, Zanotti G, Hart R, Smith S.|
|Clinical Outcomes: Oncology||POSA33||Matching-adjusted Indirect Comparisons of Avapritinib Versus Midostaurin Among Patients with Advanced Systemic Mastocytosis||Pilkington H, Smith S, Roskell N, Iannazzo S.|
|Health Policy & Regulatory: Oncology||POSA221||5-Years On: Reflections on the Cancer Drugs Fund||Critchlow S, Lilley C.
|Clinical Outcomes: Cardiovascular Disorders||POSB22||Indirect Treatment Comparisons of Empagliflozin versus Sacubitril + Valsartan for the Treatment of Patients with Heart Failure with Reduced Ejection Fraction||Smith S, Pikington H, Roskell N, Linden S, Bellanca L.|
|Methodological & Statistical Research: Oncology||POSB301||Development of a Sequencing Model Using Patient-level Data to Optimize Patient Outcomes in Multiple Myeloma||Mendes J, Boer JH, Casamassima G, Willis A, Matthijsse S, Armeni P.|
|Real World Data & Information Systems: No Specific Disease||POSB405||Data Governance for Rwd/E Management: Optimising Its Use in HTA and Decision-Making||Sigurðardóttir K, Sola-Morales O, Murphy LA, Corry S, Mestre-Ferrandiz J, Cunningham D, Akehurst R, De Pouvourville G.|
|Economic Evaluation: Oncology||POSC110||Cost-effectiveness of Durvalumab Following Chemoradiotherapy in Unresectable Stage III NSCLC Patients in the US: An Update Based on 5-year PACIFIC Data||Mooradian MJ, Taylor S, Ramsden R, Keep M, Dunlop W, Brannman L, Yong C.|
|Methodological & Statistical Research: Biologics and Biosimilars||POSC319||Analysis of Treatment Sequences across Seven Immunological Diseases and the Variability in Efficacy for Patients By Disease: Opportunities for Improvement||Boer JH, Hassan F, Alulis-Nielsen S, Lee JM, Lee D.|